文献速递神经肿瘤

免疫检查点抑制剂治疗高级别脑膜瘤:一项系统综述

Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review.
PubMed 文献 · World Neurosurg · 2024-06-18

本系统综述检索PubMed并按PRISMA指南纳入4项研究共59例复发WHO II/III级脑膜瘤患者,汇总ICIs的临床反应及可能预测疗效的肿瘤基因组特征;客观缓解与错配修复缺陷及高肿瘤突变负荷最相关,常见不良反应为肝/胰酶升高、乏力及白细胞减少/感染。

要点

  • 4项研究共59例复发II/III级脑膜瘤患者接受ICIs治疗,其中II级74.6%、III级25.4%。
  • 54%患者接受纳武利尤单抗,44%接受帕博利珠单抗,1例(2%)ICI未具名。
  • 客观缓解与错配修复缺陷及高肿瘤突变负荷最相关,常见不良反应为肝/胰酶升高(11.5%)、乏力(11.5%)及白细胞减少/感染(9%)。

核心结论

  • 检查点抑制剂是复发II/III级脑膜瘤有前景的研究性治疗,对错配修复缺陷或高肿瘤突变负荷的肿瘤可能更有效。

研究设计与样本

  • 系统综述,按PRISMA指南检索PubMed,纳入报告复发II级或III级脑膜瘤接受ICIs治疗临床数据的研究,共4项研究、59例患者。

主要发现

  • 59例患者中74.6%为WHO II级脑膜瘤,25.4%为III级脑膜瘤。
  • 肿瘤基因组数据在各研究间报告不一致,客观缓解与错配修复缺陷及高肿瘤突变负荷最相关。
  • 常见不良反应包括肝/胰酶升高(11.5%)、乏力(11.5%)及白细胞减少/感染(9%)。

临床怎么用

  • 作者认为检查点抑制剂是复发II/III级脑膜瘤有前景的研究性治疗。
  • 作者认为这些药物对存在错配修复缺陷或高肿瘤突变负荷的肿瘤可能更有效。
  • 作者提出未来研究应通过研究联盟前瞻性入组患者、描述性刻画肿瘤基因组并标准化评估影像学反应。

局限性

  • 肿瘤基因组数据在各研究间未一致报告。
  • 作者提出未来研究应通过研究联盟前瞻性入组患者、描述性刻画肿瘤基因组并标准化评估影像学反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: World Health Organization grade II/III meningiomas frequently recur despite maximal safe surgical resection and adjuvant radiation. Notoriously resistant to medical therapy, no well-established guidelines for pharmacologic treatment currently exist. In recent years, a small number of clinical trials have investigated immune checkpoint inhibitors (ICIs) for patients with recurrent grade II/III meningiomas. We reviewed the existing literature to 1) summarize the clinical responses that have been observed and 2) identify tumor genomic characteristics that may predict a better response to ICI therapy. METHODS: PubMed was searched following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to include studies reporting clinical data for recurrent grade II or grade III meningiomas treated with ICIs. Clinical features, available tumor genomics, and outcomes were analyzed. RESULTS: Four studies were included comprising 59 patients; 74.6% had World Health Organization grade II meningiomas and 25.4% had grade III meningiomas. Thirt-two patients (54%) received nivolumab, 26 (44%) received pembrolizumab, and 1 (2%) received an ICI not named. While tumor genomic data was not consistently reported across studies, favorable response was most associated with mismatch repair deficiency and high tumor mutational burden. Common adverse effects included liver/pancreas enzyme elevations (11.5%), fatigue (11.5%), and leukopenia/infection (9%). CONCLUSIONS: Checkpoint inhibitors represent a promising investigational therapy for patients with recurrent grade II/III meningiomas. These drugs may be more efficacious for tumors with mismatch repair deficiency or high tumor mutational burden. Future investigations would benefit from research consortia with prospective enrollments of patients, descriptive characterization of tumor genomics, and standardized assessment of radiographic response.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Kaye J, Na J, Atluri S, et al. Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review. World Neurosurg. 2024. PMID: 38901486. doi:10.1016/j.wneu.2024.06.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。